THCV Cannabinoid

1
Harnessing the Power of Cannabinoi ds
a
Led by a world class team, BayMedica is
developing efficient and scalable biosynthetic
and synthetic chemistry processes to deliver a
portfolio of natural cannabinoids including CBC,
CBDV, THCV and CBT as well as novel cannabinoid
analogs for life science, pharmaceutical,
nutraceutical, cosmetic and animal health
applications.
The BayMedica Platform Biosynthesis is a
multi-step process where living organisms use
enzymes to catalyze the conversion of simple
substrates into complex products.
2
Cannabinoids are one class of compounds
synthesized by Cannabis, however, the Cannabis
sativa plant is an inefflcient biological factory
for even the most prevalent compounds such as
THC and CBD, which comprise only 2-5 of the
biomass of the plant. Cannabis is even less
efkcient at synthesizing the 100 minor
cannabinoids such as CBC, CBN and CBDV that
typically comprise less than 0.1 of plant
biomass. The BayMedica platform solves this issue
by engineering common yeast to convert sugar
into cannabinoids, including common and rare
natural varieties, as well as novel cannabinoid
analogs of pharmaceutical interest. Our platform
produces rare, non-intoxicating,
naturally-occurring cannabinoids and novel
cannabinoid analogs. We also leverage our
experience in synthetic chemistry where
applicable. BayMedica cannabinoids have a wide
variety of applications in the pharmaceutical,
cosmetic, consumer and animal health
industries. .
ABO U T O U R P L AT F O R M
3
BayMedica Products
.

• Prodiol
• Our Prodiol family of natural pharmaceutical-grade
  , cannabinoids are available as individual
  ingredients for inclusion into consumer health
  and wellness products.
• We have been able to produce the rare
  cannabinoids THCV, CBDV, CBC and CBT at
  commercial scale.
• L E AR N MO R E ABO U T O U R C ANNABI NO I D P R
  O DU C T S

.
4
BayMedica is now a division of InMed
Pharmaceuticals
InMed is a global leader in the manufacturing and
development of rare cannabinoids. InMed is a
clinical-stage company developing a pipeline of
rare cannabinoid therapeutics and dedicated to
delivering new treatment alternatives to
patients that may benekt from cannabinoid-based
pharmaceutical drugs. InMed is a publicly traded
company, listed on the Nasdaq exchange under the
symbol INM.
L E AR N MO R E I NME D P HAR MAE U T I C AL S
Discover the Future of Cannabinoids
CONTACT BAYMEDICA
5
Research Development 458 Carlton Ct. South San
Francisco, CA 94080 Copyright 2022 All Rights
Reserved BayMedica U.S. Operations 930 Tahoe
Blvd, Ste. 802-433 Incline Village, NV
89451 info_at_baymedica.com 1 (650)
392-0510 Corporate HQ (InMed Pharmaceuticals)
310-815 West Hastings Street Vancouver, BC, V6C
1B4 info_at_inmedpharma.com 1 [phone]